A non-interventional observational study in adults and children from 5 years of age assessing the safety and tolerability of GRAZAX® in case of concomitant specific immunotherapy (SCIT or SLIT)
Completed
- Conditions
- grass pollen induced allergic rhinoconjunctivitisJ30.1Allergic rhinitis due to pollen
- Registration Number
- DRKS00005009
- Lead Sponsor
- ALK-Abelló Arzneimittel GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 181
Inclusion Criteria
The tolerability of the grass immunotherapy tablet (GRAZAX) during routine treatment is recorded in children and adults who are treated concomitantly with additional specific immunotherapy for treatment of further allergies.
Exclusion Criteria
Contraindications of specific immunotherapy
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method